Text Size

Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

This study has been terminated.
(terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled])
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00671528
First received: May 1, 2008
Last updated: July 16, 2012
Last verified: July 2012
History of Changes
  Purpose

This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial comparing three creams in the treatment of impetiginous eczema:

  • Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
  • Arm B: Combination of betamethasone diproprionate cream and gentamicin sulfate cream
  • Arm C: Betamethasone diproprionate cream

At 7 sites, in Portugal, a total of 207 subjects will be randomized using a 1:1:1 randomization ratio to receive one of the three possible treatments for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days. Assessments will be made of level of improvement of the target area in each treatment group, number of days for total remission, and safety profile.

Note: This study was terminated early due to lack of recruitment (only 3 of the 207 planned participants were enrolled). Statistical analyses were not performed.

Further, 7 sites were planned, but only 4 sites were approved out of which 3 sites were initiated.


Condition Intervention Phase
Dermatitis, Atopic
Eczema, Atopic
Skin Diseases, Eczematous
 Drug: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
Drug: Cream (betamethasone diproprionate and gentamicin)
Drug: Cream (betamethasone diproprionate)
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind Evaluation of the Safety and Efficacy of Quadriderme® (Betamethasone Diproprionate, Clotrimazole and Gentamicin) Compared With Betamethasone Diproprionate Combined With Gentamicin Sulfate and With Betamethasone Diproprionate in the Treatment of Impetiginous Eczema

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • Percent Improvement of Individually Measured Signs of the Disease [ Time Frame: Days 1 (prior to start of treatment), 8, 15, 21, and 28. ] [ Designated as safety issue: No ]

    Percent improvement of individually measured signs of the disease (erythema, vesiculation, scaling, pruritis) in a given target area that was chosen by the investigator was assessed objectively & quantified on a scale of 0-5 (0-absent, 5-very intense). Overall assessment reflected the changes in the disease & was carried out by the investigator.

    The following scale was used:

    1. Cure- Complete remission
    2. > 75% reduction: Marked improvement
    3. 50-75% reduction: Moderate improvement
    4. 25-50% reduction: Slight improvement
    5. <25% reduction: Ineffectiveness
    6. Worsening of signs & symptoms


Secondary Outcome Measures:
  • Number of Days Required to Achieve Total Remission [ Time Frame: Up to 28 days ] [ Designated as safety issue: No ]
    The speed of action, measured as the number of days required to achieve total remission of all signs and symptoms of the disease.


Enrollment: 3
Study Start Date: July 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: QUADRIDERME® cream
QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
 Drug: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Other Name: QUADRIDERME® cream, SCH 000411
Active Comparator: Betamethasone and Gentamicin
Combination of betamethasone diproprionate cream and gentamicin sulfate cream
 Drug: Cream (betamethasone diproprionate and gentamicin)
Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Active Comparator: Betamethasone
Betamethasone diproprionate cream
 Drug: Cream (betamethasone diproprionate)
Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Minimum age: 12 years
  • Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema).
  • Diagnosis of impetiginous eczema.
  • Ability to understand the procedures of the protocol and follow the requirements during the course of the study.
  • Results of routine laboratory tests - hemogram with leukogram and platelet count, creatinine, glucose, sed. rate, IgE level and transaminases; along with plasma cortisol and adrenocorticotropic hormone (ACTH) levels prior to the start of the treatment. These results must all be within normal limits or not clinically relevant in order to be included in the trial.

Exclusion Criteria:

  • Pregnant participants or women of childbearing age who are not using birth control methods considered reliable by the attending physician.
  • Participants with a history of hypersensitivity to any of the components of the medication being studied.
  • Participants in whom the extent or severity of the lesions requires treatment of a different type than what is planned for this trial.
  • Participants who need any other type of topical or systemic medication during the trial that might affect the course of the disease.
  • Participants who have been treated with other topical medications during the 14-day period prior to the start of the trial.
  • Participants who have received systemic corticosteroids or any other immunosuppressant medication during the 28-day period prior to the start of the study.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Vice President, Late Stage Development Group Leader, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier: NCT00671528     History of Changes
Other Study ID Numbers: P05134, EudraCT No.: 2007-004980-23
Study First Received: May 1, 2008
Results First Received: May 19, 2011
Last Updated: July 16, 2012
Health Authority: Portugal: National Pharmacy and Medicines Institute

Keywords provided by Merck:
Impetiginous

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Genetic
Genetic Diseases, Inborn
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Betamethasone-17,21-dipropionate
Betamethasone
Betamethasone sodium phosphate
Clotrimazole
Miconazole
 Gentamicins
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 13, 2013